Register
FDA approves new breakthrough therapy for cystic fibrosis |
News and Updates
eMediNexus Coverage from: 
FDA approves new breakthrough therapy for cystic fibrosis
eMediNexus,  22 October 2019
remove_red_eye 497 Views
#Pathology and Lab Medicine #Pharmacist #Public Health #Pulmonary Medicine

1 Read Comments                

The U.S. Food and Drug Administration has approved Trikafta (elexacaftor/ivacaftor/tezacaftor), the first triple combination therapy available to treat patients with the most common cystic fibrosis mutation.

Trikafta is approved for patients 12 years and older with cystic fibrosis who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is estimated to represent 90% of the cystic fibrosis population… (FDA, October 21, 2019)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now